CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and engineered receptor allows for exquisite, dose-dependent control of the neurons to generate the therapeutic effect.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 2, 2021 | Series Unknown | $28M | 1 | — | — | Detail |
Nov 10, 2020 | Grant | $670K | 1 | — | — | Detail |
Nov 5, 2019 | Series A | $15M | 1 | Versant Ventures | — | Detail |
Sep 12, 2018 | Series A | $19M | 1 | Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | — | Series Unknown |
National Institutes of Health | — | Grant |